Equitable Health Systems
Clever Cancer Care (CleverCharts & CleverChemo) Application
What is the name of your solution?
Clever Cancer Care (CleverCharts & CleverChemo) Application
Provide a one-line summary of your solution.
The applications will collect comprehensive clinical data & ensure strict adherence to cancer treatment protocols minimizing errors & patient risk.
Film your elevator pitch.
What specific problem are you solving?
85% of children in High Income Countries (HICs) survive and thrive following a cancer diagnosis. This is in stark contrast to what happens to children in low- and middle-income countries (LMICs) (where over 80% of the 400,000 children who develop cancer each year live). Due to a complex range of poverty related limitations, markedly different levels of access to quality care and rates of treatment abandonment are seen). As a result, more than 75% of these children will die of their disease. Most of these deaths are preventable.
1. Data from LMICs shows that systematic patient assessment is prone to error and rarely comprehensive. The resultant incorrect diagnosis and staging omissions have severe effects on patient health and reduce the chances of survival. Children often present to multiple treatment sites and referral information is seldom sufficient leading to repeat testing and unnecessary delays.
To ensure standarised patient cancer care across a nation it is essential to coordinate, monitor, and accurately record a patients’ information, treatment options and journey through the health service – either at a single hospital or across multiple site admissions. In order to do so a reliable and robust nationwide patient data network is required.
To best serve the individual child with cancer a data network must systematically gather the correct patient information, leading to the correct diagnosis and staging in order to choose the correct comprehensive treatment including suggesting the correct treatment site and timing of response to treatment evaluations. This data must follow the child as they are referred between sites.
2. Administration of chemotherapy at LMIC sites can be fraught with danger where protocol decisions are complex and prescriptions are almost always handwritten. With inadequate staffing capacity, prescribing errors are common and lead to unnecessary toxicity and treatment failures. Existing automated chemotherapy prescribing programmes are built for protocols used in High Income Countries, inadequately automated and prohibitively expensive.
What is your solution?
TLM has created 2 powerful medical devices to modify these entirely unacceptable LMICs Childhood cancer outcomes dramatically, with the potential of saving countless young lives. Our suite of ‘CleverCancerCare’ Applications consisting of 2 synergistic web-based applications: CleverCharts and CleverChemo:
- CleverCharts:
Our CleverCharts Paediatric Oncology Data App has been custom built to incorporate all essential clinical data points related to childhood cancer. It has been built from the bedside to the cloud and is extremely user friendly while capturing a comprehensive dataset, including the limited data required by governments in the WHO Cancer Registries Initiative (CANREG5), simplifying mandated reporting. It will support medical personnel in choosing the correct comprehensive treatment. The application has helped to maintain the integrity of patient data and can be conveniently accessed by the different sites as patients move across the country using a unique but safe patient identifier.
- CleverChemo:
An initial proof of concept Excel-based ACPP has been implemented at Muhimbili National Hospital (MNH) in Tanzania. It has led to remarkable reduction in errors recorded over the last 4 years alongside an overwhelmingly positive reception from clinical staff using the excel-ACPP. Despite its incredible success, Excel-based programs are limited due to: security issues and ability of end-users to modify formulas; difficulty automating updates and reports; and complexity of building new treatment protocols.
CleverChemo, a custom web-based ACPP, is being developed to replace the excel-based platform to overcome the outlined limitations. We estimate that its unmatched automation and data verification features will remove more than 95% of all systematic prescribing errors, ensuring every child receives treatment faithfully according to protocol-directed calculations and requirements. It will transform the potentially error prone dangerous task of calculating chemotherapy to a safe, secure reliable process and will save countless lives.
CleverChemo has been built to either work independently or communicate with CleverCharts, allowing the hospital or health service flexibility in choosing one or both will ensure strict adherence to treatment protocols and minimize human errors in chemotherapy scheduling, calculations, and other protocol directed decisions application.
CleverCancerCare has the potential to help save the lives of 100,000s of children diagnosed with cancer in LMICs worldwide. To maximize our impact, we will distribute CleverCancerCare using either a free model or a tiered social enterprise model of distribution to overcome financial barriers to access. In developing and disseminating CleverCancerCare, this project aligns with the mission of MIT Solve to impact the lives of children with cancer and empower resource-limited countries by the built equitable health system to help cure childhood cancer.
Who does your solution serve, and in what ways will the solution impact their lives?
Tumaini La Maisha (TLM) is a Tanzanian based NGO supporting the national children’s cancer service. We have developed and support the National Children’s Cancer Network, NCCN, (coordinated through Muhimbili National Hospital) and the Tanzanian Ministry of Health, Community Development, Gender, Elderly and Children (MoHCDGEC). Together we work to provide access to all aspects of paediatric oncology care free of charge to all children. TLM provides both clinical and non-clinical care to children with cancer. This includes providing all the chemotherapy to every child treated for cancer in any of the 13 sites across the NCCN.
Our objective is to involve 30 sites in the NCCN by 2025 so that no child is more than a 4 hour journey from a participating site; in order to reach the 4,000-4,500 children that develop cancer on an annual basis. The CleverCancerCare App will support the NCCN to effectively treat all of these children. The app will help to raise the survival rate of paediatric oncology patients in the country by standardising patient pathways and minimising prescribing errors. Furthermore, we aim to provide this product for all LMICs across the globe.
Over 85% of the annual 400,000 children diagnosed with cancer worldwide live in Low or Middle-Income Countries (LMICs). Less than 25% survive in LMICs due largely to poverty (leading to a markedly different access to quality care and levels of treatment abandonment). Limited training capacity and supportive infrastructure in LMIC results in fewer numbers of sub-speciality experts and inadequate adherence to appropriate treatment protocols. Therefore, this is a global problem affecting children all over the world. It is so significant that World Health Organisation (WHO) has created the Global Initiative for Childhood Cancer to reduce the number of children suffering from cancer. They have set a target to reach a rate of at least 60% survival by 2030, meaning 1 million children could be saved within the next decade. Our application has the potential to part of this agenda.
In addition, by tackling childhood cancer in LMIC’s we have the opportunity to support governments to reach not only the Sustainable Development Goal 3 by 2030 but also to improve 1, 2, 4, 5, 6, 8, 10, 16, and 17.
How are you and your team well-positioned to deliver this solution?
The team has built a solution to real problems that they encountered every day caring for children with cancer. Each member is deeply committed and brings unique and crucial expertise to this venture.
Dr. Trish Scanlan not only has over 20 years experience in Pediatric Oncology practice but also has phenomenally defeated breast cancer twice! This personal experience drives the grit and determination of this powerhouse to eradicate childhood cancer. She is the Director of the TLM Pediatric Oncology Programme in Tanzania where she oversees all operations at the Upendo Children’s Oncology ward, Ujasiri Family Hostel in Muhimbili National Hospital, MNH, and more recently the National children’s Cancer Network – supporting children’s cancer services at 11 sites all over Tanzania. Utilizing her tenure in Ireland and Africa to ensure a consistent transfer of resources and knowledge she has facilitated the partnership of the Department of Pediatrics at Muhimbili National Hospital with Children’s Health Ireland in Dublin. She has designed and supervised a master’s course in Pediatric Haaematology/ Oncology and a 10-week Intensive Pediatric Oncology Nursing certificate course based in Muhimbili University of Health and Allied Sciences, MUHAS. It was Dr. Scanlan’s ingenious desire to replace patient assessment paper files with an automated system that lead to the creation of the CleverCharts data collection system; and directly through challenges she witnessed on the ward that led to the excel-based Chemotherapy prescribing platform. She leads the team using this system and this led directly to the need to create CleverChemo to address the limitations with this first system.
Dr Jeremy Hassan (a medical resident in the US) and Mr Manuel Esther (a movement Science doctoral student) both are TLM volunteers for more than 4 years– initially in person and now remotely. They built the Excel based ACPP and advise on the CleverChemo design. They have never received any payment for their incredible support
Mr. David Sweeney is the Senior Chief Software Developer with more than 20 years experience working in industries such as, financial services, reward and recognition and medical. He has also worked as a Technical Logistician for Medicine Sans Frontiers. He previously worked for IBM in the Global Services and Microelectronics Divisions. He holds a first-class honours degree in Electronic Engineering from Dublin City University. He is driven to use his skills to serve the poor.
Mr. Mark Ashford is an IT consultant with more than 25years’ experience, specialising in the energy sector supporting extensive programmes in Africa, CIS and South America. He is founding board member of TLM UK and fully committed to supporting TLM with extensive experience in the area of data security.
Dr Rehema Laiti is the Unit Lead on the children’s oncology ward in MNH. She has driven the clinical use of the TLM Excel based ACPP among all her local oncology colleagues.
Mr William Chimwege is an IT specialist employed at MNH and is playing an essential role in embedding the CleverCharts programme in the hospital server. He has supported TLM activities for over 5 years.
Which dimension of the Challenge does your solution most closely address?
Build fundamental, resilient, and people-centered health infrastructure that makes essential services, equipment, and medicines more accessible and affordable for communities that are currently underserved;
Where our solution team is headquartered or located:
Dar es Salaam, TanzaniaOur solution's stage of development:
PilotHow many people does your solution currently serve?
1500
Why are you applying to Solve?
As our project is in the early stages we are in need of strategic business development and technological support. We hope to develop the CleverCancerCare service into a social enterprise but need expert advice on how best to achieve this model. We currently do not have sufficient funds to progress the project at the pace which we feel it should be progressing so we are also in need have financial support. We really do feel that our programme will save countless vulnerable lives and the Solve team can help make this a reality. The fact that Solve provides the dual opportunity of technical expertise and monetary support makes this programme ideal for the progression of our project. We would be thrilled to have the chance to collaborate with your team in order to effectively and efficiently eliminate suffering and deaths of children with cancer in not only Tanzania but in all LMICs.
In which of the following areas do you most need partners or support?
Business model (e.g. product-market fit, strategy & development)
Who is the Team Lead for your solution?
Dr. Trish Scanlan
What makes your solution innovative?
Electronic Management Record Systems (EMRS) and Automated Chemotherapy Prescribing Programs (ACPP), CleverCharts and CleverChemo respectively, dramatically improves protocol compliance which in turn strengthens the capacity of medical personnel to provide high-quality and effective treatment. However, commercially available software is prohibitively expensive, inadequately automated and often tailored for High Income Countries.
Less than 25% of children diagnosed with childhood cancer survive in LMICs due largely to poverty (leading to a markedly different access to quality care and levels of treatment abandonment). Limited training capacity and supportive infrastructure in LMIC results in fewer numbers of sub-speciality experts and inadequate adherence to appropriate treatment protocols.
The CleverCancerCare suite of Apps has the potential to revolutionise pediatric (and adult) oncology not just in Tanzania but in all LMICs and save thousands of lives. To maximize our impact, we will distribute CleverCancerCare using a tiered social enterprise model of distribution to overcome financial barriers to access.
What are your impact goals for the next year and the next five years, and how will you achieve them?
2022-2023 Impact goals:
- To ensure that no child in Tanzania dies unnecessarily from cancer
- To deliver high-quality cancer treatment to call children suffering from cancer in Tanzania
- All NCCN sites have access to the CleverCancerCare apps and are trained on its use
- To improve the quality of childhood and adult oncology treatment across Tanzania
- Conducting rigorous M&E and impact evaluations to measure the impact of the app and to discern if changes need to be made to scale-up the service
2022-2026 Impact goals:
- To reduce the number of children dying from childhood cancer in LIMCs
- To improve the quality of childhood and adult oncology treatment across LMICs
- Use the revenue from the social enterprise to ensure that the provision of chemotherapy drugs, health insurance, transport services and nutritional programmes are sustained throughout the NCCN in Tanzania
How are you measuring your progress toward your impact goals?
KPIs:
Reduction in childhood mortality under 5 / under 18
Reduction in deaths due to non-communicable disease; cancer
Reduction of errors in chemotherapy drug prescription
Increased adherence to protocols for chemotherapy throughout entire treatment course
Increased accuracy of disease identification
Increased accuracy of patient data
Increased number of sites in the NCCN using the CleverCancerCare Application
Increased number of medical personnel trained on the usage of CleverCancerCare Application
What is your theory of change?
The CleverCancerCare applications, developed with the context of LMIC in mind, provide practitioners an easy-to-use, safe, secure and reliable product to firstly record and monitor patient data and secondly to accurately prescribe chemotherapy treatment. CleverCharts is an application where doctors and nurses can easily enter patients data into a database to communicate accurate and secure information between staff and different medical institutions. This information can be accessed by each medical institution the patient presents at. Most importantly, the application protects the data through a data restriction/ access feature. The CleverChemo application allows medical personnel to enter data such as standard patient specific details (age, weight, nutrition status, blood pressure, cardiac function etc), laboratory results and recent documented side effects. Then the application generates an automated personalised prescription for the patient's chemotherapy prescription minimising error, omission, or the need for senior support in the calculation process. Data will also be protected by a data restriction/ access feature.
Our immediate goals is for medical practitioner's processes to become much more efficient and effective. Clever Cancer Care will support doctors and nurses to carry out their work in a safer, more secure and quicker manner. In addition, we want to achieve higher rates of accurate chemotherapy treatment prescription.
These immediate goals will link with our longer term goals which involves the reduction of childhood and adult deaths from cancer in Tanzania and in LMICs. It will also help to grow, integrate and improve the effectiveness of the NCCN and LMIC healthcare systems.
There is ample evidence that these applications can drastically reduce errors, however, these products are typically used in high-income countries. Further, we built an excel-based proof of concept of the tool for automated chemotherapy prescription, which has been successfully used on one ward for over 2 years. 10 custom built excel sheets were rapidly adopted and reduced prescription errors by more than 90% almost over night. However, the limitations of the excel-based tool has revealed the need to develop the application
We will test some of these links through regular reviews, meetings, consistent monitoring and evaluation. It will be important to take these reflections into consideration as each new site adopts the technology will need their specific context, resources and capacity appraised.
Describe the core technology that powers your solution.
CleverCharts
This system is housed on a HIPAA/GDPR compliant AWS cloud. International medical oncology coding systems have been used (ICD-10 and ICD-O) so that the data collected can be compared with any standardized data set. It is ready to be tested and launched nationwide.
On the server side the system is created using Elixir and the relational database is postgres; the front end uses bootstrap and all the source code is managed via GitHub.
CleverChemo
It will comprise of the following components: a background engine where a chemotherapy calculator operates; a library containing 3 sections (common paediatric oncology protocols; all possible disease staging systems; all common drug modification rules used to inform the chemotherapy calculator); and a user interfacing front-end for initial data entry and subsequent prescription generation. Adding a new protocol to this system would be simple and updates across all users would be possible instantly. The web-based app requires the prescribing doctor to input a limited number of simple patient and treatment-response related facts. These include: standard patient specific details (age, weight, nutrition status, blood pressure, cardiac function etc), laboratory results and recent documented side effects.
Our algorithm then automates the necessary complicated calculations minimising error, omission, or the need for senior onsite support in this process. Vital timed response-to-treatment-based alterations in management are generated and highlighted for specialist review and approval. It is important to state that there will always be a need for sub-Specialist to confirm and provide final approval to any chemotherapy prescription, but this programme allows the possibility of offsite supervision for certain oncology treatments.
CleverChemo will not store any information remotely thereby simplifying all web-based security issues. It will act in the same way as a very specialized online calculator. It generates the chemotherapy prescription which is then stored by the end-user. In the complex and challenging world of medical technology this is a very simple solution to data safety.
Which of the following categories best describes your solution?
A new application of an existing technology
Please select the technologies currently used in your solution:
Which of the UN Sustainable Development Goals does your solution address?
In which countries do you currently operate?
In which countries will you be operating within the next year?
What type of organization is your solution team?
Nonprofit
How many people work on your solution team?
Full-time: 2; part-time: 5
How long have you been working on your solution?
5 years
What is your approach to incorporating diversity, equity, and inclusivity into your work?
Our vision is to ensure that no child is left behind in the fight against cancer. This means that regardless of sex, race, religion, tribal or cultural affiliation we will provide our clinical and non-clinical services to those in need. This mission to provide high-quality cancer treatment to Tanzanian children from all walks of life underpins the philosophy of our organisation. This means equality is a core value at TLM. Diversity in our team is particularly important in an organisation that works with groups from varied backgrounds. We are aware that diversity enables the incorporation of different perspectives which are crucial when dealing with complex issues such as childhood cancer. This empowers us to be a a stronger tea m and more innovative.
We also want to ensure that we offer members from different groups equal opportunity to work with us. It is important to give all people a fair chance to join a team irrespective of their context. There is a vibrant volunteer programme at our organisation that works with local, national, regional and international people. Involving volunteers into our team creates a dynamic environment which creates diverse insights. This always adds value to our work and reaching the ultimate goal of eradicating childhood cancer. Our HR team have established a strong basis to be as welcoming and encouraging as possible to all of our current staff, new staff and our patients. We want to make sure that everyone feels heard, valued and respected.
TLM is dependent on effective partnerships as we work alongside our colleagues’ at Muhimbili National Hospital. Therefore, placing emphasis on diversity, equity, and inclusivity into our organisational structure is imperative to ensure we are a sustainable organisation and that our staff and patients feel respected, dignified and valued. In addition, as we continue to expand the National Children's Cancer Network, NCCN, across the country, we will ensure to respect and value each individual as we continue to integrate new sites into our NCCN.
These principles will also be incorporated as we launch the CleverCancerCare App. We will ensure that as we grow the service to ensure that we integrate a strong, clearly defined and thoroughly understood diversity, equity and inclusivity action plan.
What is your business model?
Our business model will be a social enterprise with a focus on a low-income client. The aim is to provide medical technology to low-income medical institutions that would otherwise be unable to afford it.This model will help us to achieve a high social impact in terms of improved healthcare and reduction in childhood mortality in Tanzania and in all LMICs. Our customers will predominantly be governments and medical institutions which in turn will principally benefit children with cancer. We will provide our customers with a set-up stage where we implement the product in their institution and train them on how to use the product. We will also provide ongoing maintenance and technical support. This application will be attractive to our clients as other programmes are unaffordable, built with high-income countries contexts in mind, assume senior expertise is on hand so none of the products are commercially available or maximally automated.
Target Market:
1. Market 1: Tanzania (free)
a. Test at Muhimbili National Hospital
b. Expansion to 30+ centres in Tanzanian National Children’s Cancer Network (NCCN)
2. Market 2: Expansion in Africa (Level 1 pricing for LMIC)
3. Market 3: Expansion Globally (Different pricing depending on site)
4. Market 4: Adult Oncology (Different pricing depending on site)
Do you primarily provide products or services directly to individuals, to other organizations, or to the government?
Organizations (B2B)What is your plan for becoming financially sustainable?
As this is a social enterprise, we would like to use grants and donors to cover the costs of the development. Products will be paid by end-users. Costs will be kept to a minimum to follow a simple revenue model to sustain product maintenance and future development. The service will be provided on a graded basis to sustain product maintenance and future development.
Variations to our CLEVER Chemo APP essential for distribution outside of Tanzania include:
- Compliance with patient data privacy laws in different countries.
- Translation to different languages
Revenue will be realized through invoicing product units:
Unit 1: Single Initiation fee: Standard CleverCancerCare Apps (standard access to CleverCharts data collecting tool; and standard library of CleverChemo automated treatment protocols and reports); training and implementation.
Unit 2: Annual Licensing fee - software and treatment guideline updates; technical support
Unit 3: Customized services including requests to:
- Programme and upload locally required treatment protocols to the CleverChemo App.
- Generate customized reports
Unit 4: Licensing fee for access to anonymised data from centralized cloud-server
Our units are priced to cover operating and development costs with a small margin:
Unit 1 and 2 Price: ongoing scheduled maintenance +development costs: training, server, technical support, updates. Patient volume may also be considered.
Unit 3 and 4 Price: Depends on scope of product customization/complexity of data and # of licenses sold
Solution Team
-
KB
-
EM
Ms Eliwangu Mlaki CFO & Donor Manger, Tumaini La Maisha
-
Dr Trish Scanlan Paediatric Oncologist and ED of Tumaini la Maisha, Tumaini la Maisha
to Top
Our Organization
Tumaini La Maisha (TLM) Tanzania